Apellis Pharmaceuticals (APLS) Announces Proposed 7M Share Common Offering

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.

Citigroup, J.P. Morgan and Evercore ISI are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The shares are being offered by Apellis pursuant to an automatically effective shelf registration statement that was filed with the Securities and Exchange Commission (“SEC”) on January 7, 2020.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Samos Energy raises $230M in NYSE IPO for energy acquisitions
• Haoxi Health closes $4M direct offering via Univest Securities